MMP3 Gene Test (Matrix Metallopeptidase 3, Stromelysin 1)

• Identify whether you carry the functional −1612 5A/6A promoter polymorphism and related variants that change MMP3 expression and have been associated with differences in arterial wall remodelling, coronary stenosis, in‑stent restenosis, carotid atherosclerosis, stroke, and blood pressure in multiple cohorts.
• Help explain patterns such as a family history of early coronary artery disease, variable responses to stent placement, or rapid vascular remodelling in the context of hypertension and inflammation, when results are interpreted in specialist settings.
• Add context to cardiovascular prognosis, since higher circulating MMP3 levels are emerging as independent predictors of cardiovascular outcomes in patients with established coronary artery disease, and promoter genotypes can influence these levels.
• Inform personalised strategies around blood pressure and lipid targets, smoking and pollution exposure, anti inflammatory and vascular support strategies, and, in research settings, antihypertensive treatment choice and stent follow up intensity.
• Clarify your baseline extracellular matrix remodelling architecture alongside lifestyle, blood markers, and imaging, so long term cardiovascular and tissue health plans can be built on both genetics and current biology.

MMP3 encodes matrix metallopeptidase 3, also known as stromelysin 1, a secreted zinc dependent protease in the matrix metalloproteinase family. It is produced mainly by connective tissue cells such as fibroblasts and vascular smooth muscle cells and is stored as a proenzyme that requires activation.

MMP3 has broad substrate specificity and can degrade many extracellular matrix components, including fibronectin, laminin, gelatin, non fibrillar collagens, and cartilage proteoglycans. It also activates other MMPs such as MMP1, MMP8, MMP9, and MMP13, as well as its own proenzyme, creating a protease cascade that amplifies matrix degradation when upregulated. The MMP3 gene lies in the MMP cluster on chromosome 11q22.3 and is regulated by cytokines, growth factors, mechanical stress, and promoter polymorphisms such as the 5A/6A variant.

MMP3 is a key enzyme in extracellular matrix remodelling during normal processes such as embryonic development, mammary gland involution, wound healing, and angiogenesis, and in disease processes such as arthritis, atherosclerosis, and tumour invasion. By degrading matrix proteins and activating other MMPs, it helps reshape tissue architecture and modulates cell migration, proliferation, and apoptosis.

In the vasculature, MMP3 alters the composition of the arterial wall, influencing plaque stability, arterial stiffness, and the remodelling response to hypertension and stent implantation. In joints and cartilage, it participates in the breakdown of proteoglycans and collagen fragments in inflammatory arthritis and degenerative joint disease. In the tumour microenvironment, stromal MMP3 can promote epithelial to mesenchymal transition, release growth factors and cell surface molecules, and support invasion and metastasis.

MMP3 sits at the intersection of inflammation, matrix remodelling, and disease progression. In cardiovascular disease, elevated MMP3 expression in arterial walls and higher circulating MMP3 levels have been associated with plaque progression, arterial stiffness, and increased risk of adverse cardiovascular outcomes in patients with coronary artery disease. The −1612 5A/6A promoter polymorphism affects MMP3 expression, with the 5A allele generally linked to higher promoter activity than the 6A allele, and has been associated with coronary stenosis, myocardial infarction, coronary calcification, restenosis after angioplasty or stenting, carotid atherosclerosis, stroke, and blood pressure differences.

Beyond the heart and vessels, MMP3 is implicated in acute inflammatory tissue injury, where animal models lacking MMP3 show reduced injury in immune complex mediated damage, and in cancer, where stromal MMP3 overexpression in mammary tissue can drive invasive tumour formation from otherwise normal epithelial cells. MMP3 is also involved in joint and cartilage degradation in arthritis and in tissue remodelling during mammary gland involution and adipogenesis. These roles make it a biologically rich but complex biomarker in advanced prevention and research.

It is easy to assume that MMP3 testing and standard cardiovascular risk factors tell you the same story, but they capture different layers of your biology. Blood pressure, lipids, glucose, and CRP show current vascular and inflammatory status; imaging and calcium scores show structural arterial changes; MMP3 genotyping reveals inherited variants that shape how aggressively your tissues remodel extracellular matrix in response to these stimuli, and MMP3 protein levels add information about current remodelling activity.

This distinction matters because you can carry MMP3 promoter genotypes associated with higher or lower expression and still maintain good arterial health when blood pressure, lipids, smoking, and inflammation are tightly controlled, and you can develop significant cardiovascular disease without high risk MMP3 alleles when conventional risk factors and environment dominate. MMP3 is best understood as a matrix remodelling and prognosis modifier layered on top of standard cardiometabolic risk.

The influence of MMP3 variants is strongly shaped by haemodynamic load, inflammation, metabolic health, and environmental exposures rather than by the gene alone, which means you have meaningful room to change the trajectory. Several modifiable factors can either buffer or amplify any genetic tendency.

• Blood pressure and arterial load: Hypertension increases mechanical strain on artery walls and stimulates matrix remodelling. Keeping blood pressure in optimal ranges reduces the stimulus for MMP3 mediated arterial remodelling and plaque destabilisation regardless of genotype.
• Lipids, apoB, and metabolic health: High apoB and LDL, insulin resistance, and central obesity drive atherosclerosis and vascular inflammation, amplifying the impact of any MMP3 differences on plaque composition and outcomes. Improving lipids and metabolic health mitigates risk across genotypes.
• Smoking and pollution: Tobacco smoke and air pollutants increase oxidative stress and inflammatory cytokines in the vasculature and lungs, increasing MMP expression and matrix degradation. Avoiding smoking and reducing exposure lowers the burden on MMP3 related pathways.
• Systemic and local inflammation: Chronic inflammatory conditions such as rheumatoid arthritis, periodontitis, or chronic infections elevate cytokines that upregulate MMP3 in joints, vessels, and tissues, increasing matrix degradation. Controlling these conditions reduces MMP3 driven damage.
• Physical activity and lifestyle: Regular exercise, good sleep, and an anti inflammatory dietary pattern influence vascular function, inflammatory tone, and remodelling, and can offset the practical impact of higher risk MMP3 genotypes on cardiovascular outcomes.

Yes, and this is the rule rather than the exception. Many people carry MMP3 5A/6A promoter genotypes that influence expression but never develop early cardiovascular disease or severe joint or tissue problems, especially when conventional risk factors are well controlled. Genetic effects on complex diseases are probabilistic and usually modest.

Similarly, individuals without clearly unfavourable MMP3 promoter genotypes can still develop significant cardiovascular or degenerative disease when blood pressure, lipids, smoking, or systemic inflammation are poorly controlled. MMP3 is one element in a polygenic and environmental landscape rather than a deterministic switch.

Common MMP3 genotypes mainly differ at the −1612 5A/6A promoter polymorphism and related variants and haplotypes that alter transcription factor binding and expression, with downstream effects on matrix remodelling and disease risk.

• 5A/5A genotype: Promoters containing the 5A allele have higher activity than those with the 6A allele, leading to higher MMP3 expression and greater extracellular matrix degradation. In vascular disease, higher MMP3 expression can facilitate outward remodelling and may reduce in‑stent restenosis risk in some contexts, but can also potentially destabilise plaques and contribute to adverse events depending on the overall environment.
• 5A/6A genotype: Intermediate promoter activity and MMP3 expression relative to the two homozygotes. This genotype is common and its impact on cardiovascular or tissue outcomes depends strongly on other risk factors and genetic variants.
• 6A/6A genotype: Associated with lower promoter activity and reduced MMP3 expression. In the vascular wall this can lead to higher extracellular matrix accumulation and increased propensity to in‑stent restenosis and arterial stenosis in some studies, although lower MMP3 might in some contexts be protective against plaque rupture. Overall, 6A6A has been associated with higher risk of coronary artery stenosis and restenosis in several cohorts.

Other promoter and regulatory polymorphisms across MMP3 can also influence expression and have been connected to autoimmune and inflammatory diseases and cancer risk and progression, but the 5A/6A variant remains the most extensively studied.

For DNA based MMP3 testing, preparation is straightforward because your promoter genotype does not change with medication or lifestyle. The main step is deciding how the result will be used, typically as part of a broader cardiovascular or tissue health panel, and ensuring that you have or will obtain up to date risk factor and imaging data to interpret the result in a useful way.

MMP3 genotyping from blood or saliva does not require fasting. If you are also measuring circulating MMP3 protein, inflammatory markers, lipids, or undergoing imaging, follow the preparation instructions for those tests, which may include fasting and medication timing guidance, so that data are consistent and comparable over time.

An MMP3 test is most valuable when the result will inform how you and your clinicians approach cardiovascular prevention, stent follow up, or tissue health within a structured precision or research setting. It is less helpful as a one off test without a plan to act on the information.

• Established coronary artery disease or stent placement in advanced care settings: In some research and specialist contexts, MMP3 5A/6A genotyping is explored as part of predicting in‑stent restenosis and long term cardiovascular outcomes and may inform intensity of monitoring and adjunctive strategies.
• Strong family history of early cardiovascular disease and interest in deep prevention: MMP3 status, alongside other vascular and inflammatory genes, can give additional nuance to prevention strategies, particularly where imaging and biomarkers suggest active remodelling.
• Chronic inflammatory or autoimmune conditions with vascular involvement: For people with rheumatoid arthritis or other systemic inflammatory diseases, MMP3 genotyping and, more importantly, MMP3 protein measurements can contribute to understanding vascular and joint remodelling risk as part of a broader panel.
• Precision performance and longevity programmes: In high detail health optimisation, MMP3 sits with other MMPs, collagen, and inflammatory genes to refine approaches to arterial, joint, and tissue health over decades.